Omnicell, Inc. (NASDAQ: OMCL) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Omnicell, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $34.00, Omnicell, Inc. trades at 35.0x trailing earnings, 1.3x sales and 1.2x book value, with an EV/EBITDA of 9.7. Over the last twelve months it generated about $1.2B of revenue and $45M of net income. It runs a gross margin of 45.1%, an operating margin of 5.3% and a net margin of 3.6%. It shows return on equity of 3.5%, return on invested capital of 2.7% and a free cash flow yield of 9.2%. On the balance sheet: a debt-to-equity ratio of 0.15 and a current ratio of 1.66. Over the past 52 weeks the share price ranged from $31.75 to $55.00, with a beta of 0.89.
Omnicell, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 10 Buy and 10 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.